XML 37 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs Stock-based compensation expense is included on the Condensed Consolidated Statements of Income and Comprehensive Income based upon the job function of the employees receiving the grants as follows (in millions):
Three Months Ended
September 30,		Nine Months Ended
September 30,
 2023202220232022
Lease and Well$16 $6 $39 $29 
Gathering and Processing Costs1 1 3 3 
Exploration Costs8 — 18 10 
General and Administrative32 27 66 57 
Total$57 $34 $126 $99 
Schedule of Weighted Average Fair Values and Valuation Assumptions Weighted average fair values and valuation assumptions used to value stock options and SARs granted during the nine-month period ended September 30, 2022 and ESPP grants during the nine-month periods ended September 30, 2023 and 2022 are as follows:
 Stock Options/SARsESPP
Nine Months Ended
September 30,		Nine Months Ended
September 30,
 202220232022
Weighted Average Fair Value of Grants$28.30 $29.39 $26.71 
Expected Volatility42.20 %38.07 %43.08 %
Risk-Free Interest Rate0.89 %5.02 %1.33 %
Dividend Yield3.28 %2.67 %2.88 %
Expected Life5.3 years0.5 years0.5 years
Schedule of Stock Options and SARs Transactions
The following table sets forth stock option and SAR transactions for the nine-month periods ended September 30, 2023 and 2022 (stock options and SARs in thousands):
Nine Months Ended
September 30, 2023		Nine Months Ended
September 30, 2022
Number of
Stock
Options/SARs		Weighted
Average
Exercise
Price		Number of
Stock
Options/SARs		Weighted
Average
Exercise
Price
Outstanding at January 14,225 $77.49 9,969 $84.37 
Granted— — 2 97.64 
Exercised (1)
(924)76.88 (4,282)91.63 
Forfeited(78)86.69 (192)84.26 
Outstanding at September 30 (2)
3,223 $77.45 5,497 $78.73 
Vested or Expected to Vest (3)
3,175 $77.38 5,344 $79.05 
Exercisable at September 30 (4)
2,646 $76.53 3,686 $84.18 
(1)The total intrinsic value of stock options/SARs exercised during the nine months ended September 30, 2023 and 2022 was $46 million and $122 million, respectively. The intrinsic value is based upon the difference between the market price of EOG's common stock on the date of exercise and the exercise price of the stock options/SARs.
(2)The total intrinsic value of stock options/SARs outstanding at September 30, 2023 and 2022 was $159 million and $194 million, respectively. At September 30, 2023 and 2022, the weighted average remaining contractual life was 3.6 years and 4.3 years, respectively.
(3)The total intrinsic value of stock options/SARs vested or expected to vest at September 30, 2023 and 2022 was $157 million and $187 million, respectively. At September 30, 2023 and 2022, the weighted average remaining contractual life was 3.6 years and 4.3 years, respectively.
(4)The total intrinsic value of stock options/SARs exercisable at September 30, 2023 and 2022 was $133 million and $114 million, respectively. At September 30, 2023 and 2022, the weighted average remaining contractual life was 3.3 years and 3.7 years, respectively.
Schedule of Restricted Stock and Restricted Stock Unit Transactions
The following table sets forth restricted stock and restricted stock unit transactions for the nine-month periods ended September 30, 2023 and 2022 (shares and units in thousands):
Nine Months Ended
September 30, 2023		Nine Months Ended
September 30, 2022
Number of
Shares and
Units		Weighted
Average
Grant Date
Fair Value		Number of
Shares and
Units		Weighted
Average
Grant Date
Fair Value
Outstanding at January 14,113 $80.77 4,680 $69.37 
Granted1,629 131.33 1,623 113.03 
Released (1)
(1,208)40.27 (1,953)82.05 
Forfeited(85)84.25 (130)65.44 
Outstanding at September 30 (2)
4,449 $110.21 4,220 $80.41 
(1)The total intrinsic value of restricted stock and restricted stock units released during the nine months ended September 30, 2023 and 2022, was $156 million and $215 million, respectively. The intrinsic value is based upon the closing price of EOG's common stock on the date the restricted stock and restricted stock units are released.
(2)The total intrinsic value of restricted stock and restricted stock units outstanding at September 30, 2023 and 2022, was $564 million and $472 million, respectively.
Schedule of Performance Award Transactions
The following table sets forth the Performance Unit transactions for the nine-month periods ended September 30, 2023 and 2022 (units in thousands):
Nine Months Ended
September 30, 2023		Nine Months Ended
September 30, 2022
Number of
Units		Weighted
Average
Grant Date Fair Value		Number of
Units		Weighted
Average
Grant Date Fair Value
Outstanding at January 1688 $83.82 679 $84.97 
Granted109 141.59 122 126.55 
Released (1)
(86)79.98 (57)136.74 
Forfeited for Performance Multiple (2)
(86)79.98 (56)136.74 
Outstanding at September 30 (3)
625 (4)$94.94 688 $83.82 
(1)The total intrinsic value of Performance Units released was $10 million and $7 million for the nine months ended September 30, 2023 and 2022, respectively. The intrinsic value is based upon the closing price of EOG's common stock on the date the Performance Units are released.
(2)Upon completion of the Performance Period for the Performance Units granted in 2019 and 2018, a performance multiple of 50% was applied to each of the grants resulting in a forfeiture of Performance Units in both February 2023 and February 2022.
(3)The total intrinsic value of Performance Units outstanding at September 30, 2023 and 2022, was approximately $79 million and $77 million, respectively.
(4)Upon the application of the relevant performance multiple at the completion of each of the remaining Performance Periods, a minimum of zero and a maximum of 1,249 Performance Units could be outstanding.